Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walt Marquardt

Interventional Cardiology Sacramento, CA Medical Doctor

NPI 1881766962 CMS profile 175664

3941 J Street, Suite 260, Sacramento, CA 95819

Open in the dashboard

General payments

$25,402

742 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$750 paid to institutions, not to them · program year 2019

Through program year 2025, Walt Marquardt of Sacramento, CA is reported in the CMS Open Payments database as having received $25,402 across 742 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $750 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,735 84
2024 General $3,119 77
2023 General $4,657 144
2022 General $4,139 142
2021 General $4,133 142
2020 General $2,058 73
2019 General $3,561 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walt Marquardt
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Walt Marquardt were reported at $3,735. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Walt Marquardt Interventional Cardiology median Middle half National median
2019 $3,561 $1,097 $329–$3,048 $163
2020 $2,058 $473 $161–$1,480 $114
2021 $4,133 $677 $233–$1,827 $132
2022 $4,139 $978 $333–$2,724 $149
2023 $4,657 $1,136 $382–$2,986 $160
2024 $3,119 $1,181 $395–$3,326 $164
2025 $3,735 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $5,583 257 payments
  2. Abiomed $5,572 124 payments
  3. Medtronic, Inc. $5,274 196 payments
  4. Inari Medical, Inc. $1,955 44 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,525 22 payments
  6. Shockwave Medical, Inc $1,317 26 payments
  7. Medtronic Vascular, Inc. $807 15 payments
  8. Chiesi USA, Inc. $577 8 payments
  9. CVRx, Inc. $545 9 payments
  10. AstraZeneca Pharmaceuticals LP $389 6 payments
  11. Other $1,858 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $25,351 740 payments
  2. Education $51 2 payments
Products named General payments · program years 2019–2025
  1. Impella $4,886 110 payments
  2. CT THROMBECTOMY SYSTEM KIT $1,705 41 payments
  3. FLOWTRIEVER CATHETER, S $1,705 41 payments
  4. LifeVest $1,525 22 payments
  5. FFRANGIO $1,085 33 payments
  6. ONYX FRONTIER $884 28 payments
  7. Telescope $858 45 payments
  8. Synergy Stents $843 26 payments
  9. SYNERGY Synergy_Ic $615 37 payments
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $595 15 payments
  11. Other $11,642 370 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

4,238

Median for Interventional Cardiology: 2,236

Drug cost

$880,299

Median for Interventional Cardiology: $380,412

Branded share of claims

32%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 336 $354,719
Entresto Sacubitril/Valsartan Brand 156 $190,176
Xarelto Rivaroxaban Brand 70 $69,198
Jardiance Empagliflozin Brand 44 $60,706
Repatha Sureclick Evolocumab Brand 56 $52,479
Farxiga Dapagliflozin Propanediol Brand 24 $33,640
Brilinta Ticagrelor Brand 27 $26,377
Repatha Syringe Evolocumab Brand 14 $16,934
Praluent Pen Alirocumab Brand 16 $13,675
Vascepa Icosapent Ethyl Brand 13 $6,646

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$362,940

Medicare's payments for the services billed

Medicare patients

1,225

Average age 77

Services billed

3,171

507 women, 718 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Arthritis 52%
Atrial fibrillation 39%
Heart failure 36%
Chronic kidney disease 32%
Diabetes 30%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$17 70 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

742 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record